Abeona Therapeutics ABEO 深 沪
已收盘 11-07 16:00:00 美东时间
4.20
+0.010
+0.24%
华盛通- 最 高4.2399
- 今 开4.15
- 成交量 260.83万股
- 最 低 4.00
- 昨 收 4.19
- 总市值 2.15亿
- 52周最高 7.5401
- 市盈率 静 --
- 换手率 5.09%
- 52周最低 3.9328
- 委 比 84.33%
- 总股本 5127.85万
- 历史最高 750.00
- 量 比 1.10
- 振 幅 5.73%
- 历史最低 2.19
- 每 手 1
- 风险率 0.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics Inc. granted restricted stock equity awards to 11 new non-executive employees, totaling up to 71,035 shares. The shares vest annually over three years, contingent on continued employment. The company specializes in cell and gene therapies, with ZEVASKYN being its flagship product for treating wounds in patients with recessive dystrophic epidermolysis bullosa.
11-03 12:30
Abeona Secures Permanent CMS J-Code J3389 For ZEVASKYN Gene Therapy In Recessive Dystrophic Epidermolysis Bullosa; New J-Code Becomes Effective January 1, 2026
Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has
10-30 22:48
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
Abeona Therapeutics announced that CMS has established a permanent HCPCS J-code (J3389) for ZEVASKYN, a gene therapy for treating wounds in RDEB patients. The code will take effect on January 1, 2026, simplifying claims processing and improving patient access. ZEVASKYN uses the patient's own skin cells to produce functional collagen, addressing a severe genetic skin disorder.
10-30 14:45
Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
Abeona Therapeutics announced the appointment of Dr. James A. Gow as Senior Vice President, Head of Clinical Development & Medical Affairs. With over 20 years of experience in gene therapy, particularly in ophthalmology, Dr. Gow has successfully led multiple FDA-approved programs. He joins Abeona as it advances cell and gene therapies for serious diseases, including ZEVASKYN for recessive dystrophic epidermolysis bullosa.
10-20 12:30
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
10-13 19:18
Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
Abeona Therapeutics' ABO-503 gene therapy for X-linked retinoschisis (XLRS) has been selected for the FDA's RDEA Pilot Program, designed to advance rare disease treatments by supporting novel efficacy endpoints. XLRS, a rare genetic retinal disorder causing severe vision loss, currently has no approved therapies. ABO-503, utilizing a functional RS1 gene delivered via a novel AAV capsid, has shown promising preclinical results, including improved ...
10-13 11:30
Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy
<p>Abeona Therapeutics and Children's Hospital Colorado have activated the hospital as a Qualified Treatment Center (QTC) for ZEVASKYN, the first gene therapy approved for treating wounds in adults and children with recessive dystrophic epidermolysis bullosa (RDEB). The therapy involves gene-modified skin cells to produce functional type VII collagen, addressing the genetic defect causing the disease. Children's Colorado, recognized as a center o...
10-08 11:30
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Abeona Therapeutics Inc. announced that its management team will participate in two upcoming investor conferences in September 2025: a fireside chat at the Cantor Global Healthcare Conference on September 4 and a presentation at the H.C. Wainwright Global Investment Conference on September 9. Both events will be webcast live and available for replay on the company’s website. Abeona, a biopharmaceutical company, develops cell and gene therapies fo...
08-29 11:30
Krystal Biotech adjusts pipeline to prioritize inhaled antitumor agent
Krystal Biotech (NASDAQ:KRYS) announced Thursday a revamped product pipeline after a decision to prioritize studies for an inhaled version of its antitumor candidate KB707 targeted at non-small cell l...
08-22 00:59
